{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:21:13Z","timestamp":1789759273821,"version":"4.0.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"DOI":"10.7759\/cureus.53400","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T15:27:56Z","timestamp":1706801276000},"source":"Crossref","is-referenced-by-count":7,"title":["Etiology of Drug-Induced Edema: A Review of Dihydropyridine, Thiazolidinedione, and Other Medications Causing Edema"],"prefix":"10.7759","author":[{"given":"Evan  S","family":"Sinnathamby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bretton  T","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert  A","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan  T","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey  J","family":"De Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Mouhaffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Willett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260742","article-title":"Peripheral edema: a common and persistent health problem for older Americans","volume":"16","author":"Besharat S","year":"2021","unstructured":"Besharat S, Grol-Prokopczyk H, Gao S, Feng C, Akwaa F, Gewandter JS. Peripheral edema: a common and persistent health problem for older Americans. PLoS One. 2021, 16:e0260742. 10.1371\/journal.pone.0260742","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12648","article-title":"The impact of lower limb chronic oedema on patients' quality of life","volume":"14","author":"Greene A","year":"2017","unstructured":"Greene A, Meskell P. The impact of lower limb chronic oedema on patients' quality of life. Int Wound J. 2017, 14:561-8. 10.1111\/iwj.12648","journal-title":"Int Wound J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061669","article-title":"Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy","volume":"19","author":"Mansilha A","year":"2018","unstructured":"Mansilha A, Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018, 19:1669. 10.3390\/ijms19061669","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12224","article-title":"Chronic oedema\/lymphoedema: under-recognised and under-treated","volume":"12","author":"Keast DH","year":"2015","unstructured":"Keast DH, Despatis M, Allen JO, Brassard A. Chronic oedema\/lymphoedema: under-recognised and under-treated. Int Wound J. 2015, 12:328-33. 10.1111\/iwj.12224","journal-title":"Int Wound J"},{"key":"ref5","article-title":"Cerebral Edema","author":"Nehring SM","year":"2019","unstructured":"Nehring SM, Tadi P, Tenny S. Cerebral Edema. StatPearls, Treasure Island, FL; 2019."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2004.06.002","article-title":"Macular edema","volume":"49","author":"Tranos PG","year":"2004","unstructured":"Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Surv Ophthalmol. 2004, 49:470-90. 10.1016\/j.survophthal.2004.06.002","journal-title":"Surv Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.12-RAI-0493","article-title":"Recent advances in drug-induced angioedema","volume":"61","author":"Inomata N","year":"2012","unstructured":"Inomata N. Recent advances in drug-induced angioedema. Allergol Int. 2012, 61:545-57. 10.2332\/allergolint.12-RAI-0493","journal-title":"Allergol Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14752","article-title":"Drug-induced peripheral oedema: an aetiology-based review","volume":"87","author":"Largeau B","year":"2021","unstructured":"Largeau B, Cracowski JL, Lengell\u00e9 C, Sautenet B, Jonville-B\u00e9ra AP. Drug-induced peripheral oedema: an aetiology-based review. Br J Clin Pharmacol. 2021, 87:3043-55. 10.1111\/bcp.14752","journal-title":"Br J Clin Pharmacol"},{"key":"ref9","article-title":"","author":"Lent-Schochet D","year":"2019","unstructured":"Lent-Schochet D, Jialal I. Physiology, Edema. StatPearls, Treasure Island, FL; 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537065\/."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq062","article-title":"Microvascular fluid exchange and the revised Starling principle","volume":"87","author":"Levick JR","year":"2010","unstructured":"Levick JR, Michel CC. Microvascular fluid exchange and the revised Starling principle. Cardiovasc Res. 2010, 87:198-210. 10.1093\/cvr\/cvq062","journal-title":"Cardiovasc Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq143","article-title":"Transcapillary exchange: role and importance of the interstitial fluid pressure and the extracellular matrix","volume":"87","author":"Reed RK","year":"2010","unstructured":"Reed RK, Rubin K. Transcapillary exchange: role and importance of the interstitial fluid pressure and the extracellular matrix. Cardiovasc Res. 2010, 87:211-7. 10.1093\/cvr\/cvq143","journal-title":"Cardiovasc Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aer515","article-title":"Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy","volume":"108","author":"Woodcock TE","year":"2012","unstructured":"Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012, 108:384-94. 10.1093\/bja\/aer515","journal-title":"Br J Anaesth"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60113","article-title":"Immune cells control skin lymphatic electrolyte homeostasis and blood pressure","volume":"123","author":"Wiig H","year":"2013","unstructured":"Wiig H, Schr\u00f6der A, Neuhofer W, et al.. Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest. 2013, 123:2803-15. 10.1172\/JCI60113","journal-title":"J Clin Invest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011013231806","article-title":"The management of burns","volume":"323","author":"Deitch EA","year":"1990","unstructured":"Deitch EA. The management of burns. N Engl J Med. 1990, 323:1249-53. 10.1056\/NEJM199011013231806","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197908303010902","article-title":"Mechanisms of edema formation in myxedema--increased protein extravasation and relatively slow lymphatic drainage","volume":"301","author":"Parving HH","year":"1979","unstructured":"Parving HH, Hansen JM, Nielsen SL, Rossing N, Munck O, Lassen NA. Mechanisms of edema formation in myxedema--increased protein extravasation and relatively slow lymphatic drainage. N Engl J Med. 1979, 301:460-5. 10.1056\/NEJM197908303010902","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James PA","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al.. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014, 311:507-20. 10.1001\/jama.2013.284427","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283472643","article-title":"Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials","volume":"29","author":"Makani H","year":"2011","unstructured":"Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, Messerli FH. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens. 2011, 29:1270-80. 10.1097\/HJH.0b013e3283472643","journal-title":"J Hypertens"},{"key":"ref18","article-title":"Calcium Channel Blockers","author":"McKeever RG","year":"202220238","unstructured":"McKeever RG, Hamilton RJ. Calcium Channel Blockers. StatPearls, Treasure Island, FL; 202220238."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200110000-00017","article-title":"Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension","volume":"38","author":"Zanchetti A","year":"2001","unstructured":"Zanchetti A, Omboni S, La Commare P, De Cesaris R, Palatini P. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol. 2001, 38:642-50. 10.1097\/00005344-200110000-00017","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-7061(01)02178-1","article-title":"Vasodilatory edema: a common side effect of antihypertensive therapy","volume":"14","author":"Messerli FH","year":"2001","unstructured":"Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens. 2001, 14:978-9. 10.1016\/s0895-7061(01)02178-1","journal-title":"Am J Hypertens"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2008.03.007","article-title":"Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade","volume":"4","author":"Blankstein R","year":"2008","unstructured":"Blankstein R, Bakris GL. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. Heart Fail Clin. 2008, 4:425-38. 10.1016\/j.hfc.2008.03.007","journal-title":"Heart Fail Clin"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-7061(02)03087-x","article-title":"Pedal edema--not all dihydropyridine calcium antagonists are created equal","volume":"15","author":"Messerli FH","year":"2002","unstructured":"Messerli FH, Grossman E. Pedal edema--not all dihydropyridine calcium antagonists are created equal. Am J Hypertens. 2002, 15:1019-20. 10.1016\/s0895-7061(02)03087-x","journal-title":"Am J Hypertens"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001201","article-title":"Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension","volume":"15","author":"Pedrinelli R","year":"2001","unstructured":"Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens. 2001, 15:455-61. 10.1038\/sj.jhh.1001201","journal-title":"J Hum Hypertens"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198710001-00023","article-title":"Microvascular mechanisms involved in calcium antagonist edema formation","volume":"10","author":"Gustafsson D","year":"1987","unstructured":"Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol. 1987, 10:S121-31. 10.1097\/00005344-198710001-00023","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref25","article-title":"Microvascular effects and oedema formation of felodipine in man","volume":"7","author":"Gustafsson D","year":"1989","unstructured":"Gustafsson D, L\u00e4nne T, Bjerkhoel P, Johansson P, Lundvall J. Microvascular effects and oedema formation of felodipine in man. J Hypertens Suppl. 1989, 7:S161-7; discussion S168.","journal-title":"J Hypertens Suppl"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2003.02402.x","article-title":"Calcium channel blocker\u2010related peripheral edema: Can it be resolved?","volume":"21","author":"Sica DA","year":"2007","unstructured":"Sica DA. Calcium channel blocker\u2010related peripheral edema: Can it be resolved?. J Clin Hypertens. 2007, 21:291-5. 10.1111\/j.1524-6175.2003.02402.x","journal-title":"J Clin Hypertens"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.29.3.751","article-title":"Calcium channel blockers blunt postural cutaneous vasoconstriction in hypertensive patients","volume":"29","author":"Iabichella ML","year":"1997","unstructured":"Iabichella ML, Dell'Omo G, Melillo E, Pedrinelli R. Calcium channel blockers blunt postural cutaneous vasoconstriction in hypertensive patients. Hypertension. 1997, 29:751-6. 10.1161\/01.hyp.29.3.751","journal-title":"Hypertension"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(03)80332-6","article-title":"A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study","volume":"25","author":"Malacco E","year":"2003","unstructured":"Malacco E, Var\u00ec N, Capuano V, Spagnuolo V, Borgnino C, Palatini P. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther. 2003, 25:2765-80. 10.1016\/s0149-2918(03)80332-6","journal-title":"Clin Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011626.pub3","article-title":"Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia","volume":"11","author":"Padhani ZA","year":"2023","unstructured":"Padhani ZA, Gangwani MK, Sadaf A, Hasan B, Colan S, Alvi N, Das JK. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database Syst Rev. 2023, 11:CD011626. 10.1002\/14651858.CD011626.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198810000-00006","article-title":"Effects of calcium antagonists on myogenic and neurogenic control of resistance and capacitance vessels in cat skeletal muscle","volume":"12","author":"Gustafsson D","year":"1988","unstructured":"Gustafsson D, Gr\u00e4nde PO, Borgstr\u00f6m P, Lindberg L. Effects of calcium antagonists on myogenic and neurogenic control of resistance and capacitance vessels in cat skeletal muscle. J Cardiovasc Pharmacol. 1988, 12:413-22. 10.1097\/00005344-198810000-00006","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199909000-00005","article-title":"Acute hypotensive, natriuretic, and hormonal effects of nifedipine in salt-sensitive and salt-resistant black normotensive and hypertensive subjects","volume":"34","author":"Damasceno A","year":"1999","unstructured":"Damasceno A, Santos A, Pestana M, Serr\u00e3o P, Caupers P, Soares-da-Silva P, Pol\u00f3nia J. Acute hypotensive, natriuretic, and hormonal effects of nifedipine in salt-sensitive and salt-resistant black normotensive and hypertensive subjects. J Cardiovasc Pharmacol. 1999, 34:346-53. 10.1097\/00005344-199909000-00005","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1097\/00004872-199608000-00016","article-title":"Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention?","volume":"14","author":"van Hamersvelt HW","year":"1996","unstructured":"van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RA, Huysmans FT. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention?. J Hypertens. 1996, 14:1041-5.","journal-title":"J Hypertens"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1999.79.3.703","article-title":"Microvascular permeability","volume":"79","author":"Michel CC","year":"1999","unstructured":"Michel CC, Curry FE. Microvascular permeability. Physiol Rev. 1999, 79:703-61. 10.1152\/physrev.1999.79.3.703","journal-title":"Physiol Rev"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200305000-00026","article-title":"Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine","volume":"21","author":"Lund-Johansen P","year":"2003","unstructured":"Lund-Johansen P, Stranden E, Helberg S, et al.. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens. 2003, 21:1003-10. 10.1097\/00004872-200305000-00026","journal-title":"J Hypertens"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/08038020310000087","article-title":"Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial","volume":"1","author":"Borghi C","year":"2003","unstructured":"Borghi C, Prandin MG, Dormi A, Ambrosioni E. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl. 2003, 1:14-21. 10.1080\/08038020310000087","journal-title":"Blood Press Suppl"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-7061(02)03000-5","article-title":"Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives","volume":"15","author":"Leonetti G","year":"2002","unstructured":"Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002, 15:932-40. 10.1016\/s0895-7061(02)03000-5","journal-title":"Am J Hypertens"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04363.x","article-title":"At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study","volume":"38","author":"Hermans L","year":"1994","unstructured":"Hermans L, Deblander A, De Keyser P, Scheys I, Lesaffre E, Westelinck KJ. At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. Br J Clin Pharmacol. 1994, 38:335-40. 10.1111\/j.1365-2125.1994.tb04363.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/BF00202163","article-title":"Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring","volume":"48","author":"Kubota K","year":"1995","unstructured":"Kubota K, Pearce GL, Inman WH. Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring. Eur J Clin Pharmacol. 1995, 48:1-7. 10.1007\/BF00202163","journal-title":"Eur J Clin Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.7.693","article-title":"Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life","volume":"159","author":"Anderson RB","year":"1999","unstructured":"Anderson RB, Hollenberg NK, Williams GH. Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. Arch Intern Med. 1999, 159:693-700. 10.1001\/archinte.159.7.693","journal-title":"Arch Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14436","article-title":"Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: a systematic review and network meta-analysis","volume":"24","author":"Liang L","year":"2022","unstructured":"Liang L, Kung JY, Mitchelmore B, Cave A, Banh HL. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: a systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2022, 24:536-54. 10.1111\/jch.14436","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1978.sp012136","article-title":"The effects of position and skin temperature on the capillary pressures in the fingers and toes","volume":"274","author":"Levick JR","year":"1978","unstructured":"Levick JR, Michel CC. The effects of position and skin temperature on the capillary pressures in the fingers and toes. J Physiol. 1978, 274:97-109. 10.1113\/jphysiol.1978.sp012136","journal-title":"J Physiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)80424-5","article-title":"D042: Vasodilatory edema: synergistic effect of high-dose calcium antagonist\/ace inhibitor combination therapy","volume":"12","author":"Messerli FH","year":"1999","unstructured":"Messerli FH, Feng Z, Michalewicz L. D042: Vasodilatory edema: synergistic effect of high-dose calcium antagonist\/ace inhibitor combination therapy. Am J Hypertens. 1999, 12:121A. 10.1016\/S0895-7061(99)80424-5","journal-title":"Am J Hypertens"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2007.10.019","article-title":"Comparison of obstructive sleep apnea patients with and without leg edema","volume":"9","author":"Iftikhar I","year":"2008","unstructured":"Iftikhar I, Ahmed M, Tarr S, Zyzanski SJ, Blankfield RP. Comparison of obstructive sleep apnea patients with and without leg edema. Sleep Med. 2008, 9:890-3. 10.1016\/j.sleep.2007.10.019","journal-title":"Sleep Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90537-7","article-title":"Correlation of intraabdominal fat accumulation and left ventricular performance in obesity","volume":"64","author":"Nakajima T","year":"1989","unstructured":"Nakajima T, Fujioka S, Tokunaga K, Matsuzawa Y, Tarui S. Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. Am J Cardiol. 1989, 64:369-73. 10.1016\/0002-9149(89)90537-7","journal-title":"Am J Cardiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-7061(01)02167-7","article-title":"Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists","volume":"14","author":"Weir MR","year":"2001","unstructured":"Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens. 2001, 14:963-8. 10.1016\/s0895-7061(01)02167-7","journal-title":"Am J Hypertens"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(00)01199-1","article-title":"Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension","volume":"86","author":"Messerli FH","year":"2000","unstructured":"Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000, 86:1182-7. 10.1016\/s0002-9149(00)01199-1","journal-title":"Am J Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.35.2.621","article-title":"Amlodipine, enalapril, and dependent leg edema in essential hypertension","volume":"35","author":"Pedrinelli R","year":"2000","unstructured":"Pedrinelli R, Dell'Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension. 2000, 35:621-5. 10.1161\/01.hyp.35.2.621","journal-title":"Hypertension"},{"key":"ref48","article-title":"Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties","volume":"2","author":"Herbette LG","year":"1998","unstructured":"Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl. 1998, 2:10-7.","journal-title":"Blood Press Suppl"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.08.007","article-title":"Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema","volume":"124","author":"Makani H","year":"2011","unstructured":"Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011, 124:128-35. 10.1016\/j.amjmed.2010.08.007","journal-title":"Am J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(89)90084-0","article-title":"New generation dihydropyridine calcium entry blockers: in search of greater selectivity for one tissue subtype","volume":"20","author":"Ohtsuka M","year":"1989","unstructured":"Ohtsuka M, Yokota M, Kodama I, Yamada K, Shibata S. New generation dihydropyridine calcium entry blockers: in search of greater selectivity for one tissue subtype. Gen Pharmacol. 1989, 20:539-56. 10.1016\/0306-3623(89)90084-0","journal-title":"Gen Pharmacol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(07)80079-8","article-title":"Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study","volume":"29","author":"Fogari R","year":"2007","unstructured":"Fogari R, Malamani G, Zoppi A, Mugellini A, Rinaldi A, Fogari E, Perrone T. Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. Clin Ther. 2007, 29:413-8. 10.1016\/s0149-2918(07)80079-8","journal-title":"Clin Ther"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)90002-3","article-title":"Thiazolidinediones: an update","volume":"355","author":"Schoonjans K","year":"2000","unstructured":"Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet. 2000, 355:1008-10. 10.1016\/S0140-6736(00)90002-3","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1414","article-title":"Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes","volume":"41","author":"Montvida O","year":"2018","unstructured":"Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018, 41:69-78. 10.2337\/dc17-1414","journal-title":"Diabetes Care"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022, 45:S17-38. 10.2337\/dc22-S002","journal-title":"Diabetes Care"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki M","year":"2006","unstructured":"Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006, 116:1802-12. 10.1172\/JCI29103","journal-title":"J Clin Invest"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29189","article-title":"Insulin resistance and pancreatic beta cell failure","volume":"116","author":"Kasuga M","year":"2006","unstructured":"Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest. 2006, 116:1756-60. 10.1172\/JCI29189","journal-title":"J Clin Invest"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/s1043-2760(00)00306-4","article-title":"PPAR gamma and the treatment of insulin resistance","volume":"11","author":"Olefsky JM","year":"2000","unstructured":"Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab. 2000, 11:362-8. 10.1016\/s1043-2760(00)00306-4","journal-title":"Trends Endocrinol Metab"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.02.051","article-title":"Treatment of insulin resistance in diabetes mellitus","volume":"490","author":"Lebovitz HE","year":"2004","unstructured":"Lebovitz HE, Banerji MA. Treatment of insulin resistance in diabetes mellitus. Eur J Pharmacol. 2004, 490:135-46. 10.1016\/j.ejphar.2004.02.051","journal-title":"Eur J Pharmacol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.70.1.341","article-title":"Peroxisome proliferator-activated receptor gamma and metabolic disease","volume":"70","author":"Willson TM","year":"2001","unstructured":"Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 2001, 70:341-67. 10.1146\/annurev.biochem.70.1.341","journal-title":"Annu Rev Biochem"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(02)02557-2","article-title":"Rationale for and role of thiazolidinediones in type 2 diabetes mellitus","volume":"90","author":"Lebovitz HE","year":"2002","unstructured":"Lebovitz HE. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol. 2002, 90:34-41G. 10.1016\/s0002-9149(02)02557-2","journal-title":"Am J Cardiol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"Mayerson AB","year":"2002","unstructured":"Mayerson AB, Hundal RS, Dufour S, et al.. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002, 51:797-802. 10.2337\/diabetes.51.3.797","journal-title":"Diabetes"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.4.710","article-title":"Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone","volume":"24","author":"Miyazaki Y","year":"2001","unstructured":"Miyazaki Y, Mahankali A, Matsuda M, et al.. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001, 24:710-9. 10.2337\/diacare.24.4.710","journal-title":"Diabetes Care"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1210\/rp.56.1.265","article-title":"Insulin resistance and its treatment by thiazolidinediones","volume":"56","author":"Lebovitz HE","year":"2001","unstructured":"Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001, 56:265-94. 10.1210\/rp.56.1.265","journal-title":"Recent Prog Horm Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.8.2460","article-title":"Therapeutic roles of peroxisome proliferator-activated receptor agonists","volume":"54","author":"Staels B","year":"2005","unstructured":"Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005, 54:2460-70. 10.2337\/diabetes.54.8.2460","journal-title":"Diabetes"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the forgotten diabetes medications","volume":"19","author":"Lebovitz HE","year":"2019","unstructured":"Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019, 19:151. 10.1007\/s11892-019-1270-y","journal-title":"Curr Diab Rep"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2289","article-title":"Use of antidiabetic drugs in the U.S., 2003-2012","volume":"37","author":"Hampp C","year":"2014","unstructured":"Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014, 37:1367-74. 10.2337\/dc13-2289","journal-title":"Diabetes Care"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003","volume":"108","author":"Nesto RW","year":"2003","unstructured":"Nesto RW, Bell D, Bonow RO, et al.. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003, 108:2941-8. 10.1161\/01.CIR.0000103683.99399.7E","journal-title":"Circulation"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200605000-00011","article-title":"Diabetic macular edema associated with glitazone use","volume":"26","author":"Ryan EH Jr","year":"2006","unstructured":"Ryan EH Jr, Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S, Williams DF. Diabetic macular edema associated with glitazone use. Retina. 2006, 26:562-70. 10.1097\/00006982-200605000-00011","journal-title":"Retina"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.4158\/EP.9.5.406","article-title":"Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications","volume":"9","author":"Mudaliar S","year":"2003","unstructured":"Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003, 9:406-16. 10.4158\/EP.9.5.406","journal-title":"Endocr Pract"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-1008-1","article-title":"Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability","volume":"46","author":"Idris I","year":"2003","unstructured":"Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia. 2003, 46:288-90. 10.1007\/s00125-002-1008-1","journal-title":"Diabetologia"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.1938","article-title":"Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes","volume":"172","author":"Idris I","year":"2012","unstructured":"Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med. 2012, 172:1005-11. 10.1001\/archinternmed.2012.1938","journal-title":"Arch Intern Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17082-x","article-title":"Structures of PPAR\u03b3 complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs","volume":"7","author":"Lee MA","year":"2017","unstructured":"Lee MA, Tan L, Yang H, Im YG, Im YJ. Structures of PPAR\u03b3 complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs. Sci Rep. 2017, 7:16837. 10.1038\/s41598-017-17082-x","journal-title":"Sci Rep"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0272","article-title":"Lobeglitazone: a novel thiazolidinedione for the management of type 2","volume":"45","author":"Bae J","year":"2021","unstructured":"Bae J, Park T, Kim H, Lee M, Cha BS.  Lobeglitazone: a novel thiazolidinedione for the management of type 2. Diabetes Metab J. 2021, 45:326-36. 10.4093\/dmj.2020.0272","journal-title":"Diabetes Metab J"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.02.021","article-title":"The \u03b12\u03b4-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions","volume":"22","author":"Chen J","year":"2018","unstructured":"Chen J, Li L, Chen SR, et al.. The \u03b12\u03b4-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions. Cell Rep. 2018, 22:2307-21. 10.1016\/j.celrep.2018.02.021","journal-title":"Cell Rep"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112807","article-title":"Gabapentinoid-induced peripheral edema and acute heart failure: A translational study combining pharmacovigilance data and in vitro animal experiments","volume":"149","author":"Largeau B","year":"2022","unstructured":"Largeau B, Bordy R, Pasqualin C, et al.. Gabapentinoid-induced peripheral edema and acute heart failure: A translational study combining pharmacovigilance data and in vitro animal experiments. Biomed Pharmacother. 2022, 149:112807. 10.1016\/j.biopha.2022.112807","journal-title":"Biomed Pharmacother"},{"key":"ref76","article-title":"Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology","volume":"89","author":"Borovac JA","year":"2016","unstructured":"Borovac JA. Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016, 89:37-47.","journal-title":"Yale J Biol Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini R","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007, 356:39-46. 10.1056\/NEJMoa054830","journal-title":"N Engl J Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.6.noc60158","article-title":"Risk factors for the development of pedal edema in patients using pramipexole","volume":"64","author":"Kleiner-Fisman G","year":"2007","unstructured":"Kleiner-Fisman G, Fisman DN. Risk factors for the development of pedal edema in patients using pramipexole. Arch Neurol. 2007, 64:820-4. 10.1001\/archneur.64.6.noc60158","journal-title":"Arch Neurol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X15666170630163616","article-title":"Antipsychotic drugs: From receptor-binding profiles to metabolic side effects","volume":"16","author":"Siafis S","year":"2018","unstructured":"Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic drugs: From receptor-binding profiles to metabolic side effects. Curr Neuropharmacol. 2018, 16:1210-23. 10.2174\/1570159X15666170630163616","journal-title":"Curr Neuropharmacol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.183089","article-title":"Self\u2011limiting atypical antipsychotics\u2011induced edema: clinical cases and systematic review","volume":"38","author":"Umar MU","year":"2016","unstructured":"Umar MU, Abdullahi AT. Self\u2011limiting atypical antipsychotics\u2011induced edema: clinical cases and systematic review. Indian J Psychol Med. 2016, 38:182-8. 10.4103\/0253-7176.183089","journal-title":"Indian J Psychol Med"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.981407","article-title":"Nitrate therapy: new aspects concerning molecular action and tolerance","volume":"123","author":"M\u00fcnzel T","year":"2011","unstructured":"M\u00fcnzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation. 2011, 123:2132-44. 10.1161\/CIRCULATIONAHA.110.981407","journal-title":"Circulation"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(02)02233-6","article-title":"Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema","volume":"89","author":"Frishman WH","year":"2002","unstructured":"Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol. 2002, 89:18-25D. 10.1016\/s0002-9149(02)02233-6","journal-title":"Am J Cardiol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome","volume":"5","author":"Schrier RW","year":"2010","unstructured":"Schrier RW, Masoumi A, Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol. 2010, 5:1132-40. 10.2215\/CJN.01410210","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu D","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, et al.. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013, 9:30. 10.1186\/1710-1492-9-30","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106081","article-title":"ACE inhibitor-mediated angioedema","volume":"78","author":"Montinaro V","year":"2020","unstructured":"Montinaro V, Cicardi M. ACE inhibitor-mediated angioedema. Int Immunopharmacol. 2020, 78:106081. 10.1016\/j.intimp.2019.106081","journal-title":"Int Immunopharmacol"},{"key":"ref86","article-title":"Acquired Angioedema","author":"Swanson TJ","year":"2023","unstructured":"Swanson TJ, Patel BC. Acquired Angioedema. StatPearls, Treasure Island, FL; 2023."},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3027530","article-title":"Insulin edema syndrome due to rapid glucose correction in a diabetic patient","volume":"2022","author":"Hussien SM","year":"2022","unstructured":"Hussien SM, Imanli H, Tran DH, Chow RD, Sood A. Insulin edema syndrome due to rapid glucose correction in a diabetic patient. Case Rep Med. 2022, 2022:3027530. 10.1155\/2022\/3027530","journal-title":"Case Rep Med"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5043752","article-title":"A rare and lethal complication: cerebral edema in the adult patient with diabetic ketoacidosis","volume":"2018","author":"Meaden CW","year":"2018","unstructured":"Meaden CW, Kushner BJ, Barnes S. A rare and lethal complication: cerebral edema in the adult patient with diabetic ketoacidosis. Case Rep Emerg Med. 2018, 2018:5043752. 10.1155\/2018\/5043752","journal-title":"Case Rep Emerg Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/217309-etiology-of-drug-induced-edema-a-review-of-dihydropyridine-thiazolidinedione-and-other-medications-causing-edema","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:14:39Z","timestamp":1707509679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/217309-etiology-of-drug-induced-edema-a-review-of-dihydropyridine-thiazolidinedione-and-other-medications-causing-edema"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":88,"URL":"https:\/\/doi.org\/10.7759\/cureus.53400","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}